Alzheimer's drug slowed cognitive decline overall in trial, but with major side effects for some

An experimental Alzheimer's disease drug from Eisai and Biogen slowed cognitive decline in a closely watched trial but may carry a risk of dangerous side effects for certain patients, according to new data presented on Tuesday.

Related Keywords

Mayo Clinic In Rochester ,Minnesota ,United States ,Japan ,Tokyo ,Massachusetts ,California ,Cambridge ,Cambridgeshire ,United Kingdom ,Canada ,San Francisco ,Howard Fillit ,Ivan Cheung ,Paul Aisen ,Dominick Reuter ,Ronald Petersen ,Drug Administration ,Alzheimer Drug Discovery Foundation ,Alzheimer Association ,Mayo Clinic ,Getty Images ,Southern California Alzheimer ,Therapeutic Research Institute ,New England Journal ,Clinical Trials ,Drug Discovery Foundation ,Massachusetts Based Biogen ,